CoChat

Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants

Open access

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To assess the reversibility of the elevation of serum creatinine levels in patients with diabetes after 5 years of continuous on-trial fenofibrate therapy. RESEARCH DESIGN AND METHODS: An on-drug/off-drug ancillary study to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial to investigate posttrial changes in serum creatinine and cystatin C. Eligible participants were recruited into a prospective, nested, three-group study based on retrospective on-trial serum creatinine levels: fenofibrate case subjects (n = 321, ≥20% increase after 3 months of therapy); fenofibrate control subjects (n = 175, ≤2% increase); and placebo control subjects (n = 565). Serum creatinine and cystatin C were measured at trial end and 6–8 weeks after discontinuation of trial therapy. RESULTS: At trial end, case subjects had the highest adjusted serum creatinine (± SE) mg/dL (1.11 ± 0.02) and the lowest adjusted estimated glomerular filtration rate (eGFR) (± SE) mL/min/1.73 m2 (68.4 ± 1.0) versus control subjects (1.01 ± 0.02; 74.8 ± 1.3) and placebo subjects (0.98 ± 0.01; 77.8 ± 0.7). After 51 days off-drug, serum creatinine in case subjects was still higher (0.97 ± 0.02) and eGFR still lower (77.8 ± 1.0) than control subjects (0.90 ± 0.02; 81.8 ± 1.3) but not different from placebo subjects (0.99 ± 0.01; 76.6 ± 0.7). Changes in serum cystatin C recapitulated the serum creatinine changes. CONCLUSIONS: Participants with significant initial on-trial increases in serum creatinine (≥20%) returned to the same level of renal function as participants receiving placebo while participants who had ≤2% increase in serum creatinine had net preservation of renal function compared with the same unselected placebo reference group. The fenofibrate-associated on-trial increases in serum creatinine were reversible, and the reversal was complete after 51 days off-drug. The similarity of the cystatin C results suggests that the mechanism of this change is not specific for serum creatinine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-1811

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Time course values of adjusted serum creatinine and cystatin C by ACCORD Renal Study Group. A: The changes in serum creatinine in units of mg/dL. B: Changes in cystatin C in units of mg/dL. The horizontal trial time point axis is not shown to scale. The study group trends are shown as: black circles, fenofibrate cases; red triangles, fenofibrate controls; blue crosses, placebo controls. Base, baseline visit; M4, month 4 visit; Close, close-out visit; Post, postclose-out visit. (A high-quality color representation of this figure is available in the online issue.)
Figure 1 Time course values of adjusted serum creatinine and cystatin C by ACCORD Renal Study Group. A: The changes in serum creatinine in units of mg/dL. B: Changes in cystatin C in units of mg/dL. The horizontal trial time point axis is not shown to scale. The study group trends are shown as: black circles, fenofibrate cases; red triangles, fenofibrate controls; blue crosses, placebo controls. Base, baseline visit; M4, month 4 visit; Close, close-out visit; Post, postclose-out visit. (A high-quality color representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
Figure 2 Time course values of adjusted eGFR and cGFR by ACCORD Renal Study Group. A: The changes in eGFR in units of mL/min/1.73 m2. B: Changes in cGFR in units of mL/min/1.73 m2. The horizontal trial time point axis is not shown to scale. The study group trends are shown as: black circles, fenofibrate cases; red triangles, fenofibrate controls; blue crosses, placebo controls. Base, baseline visit; M4, month 4 visit; Close, close-out visit; Post, postclose-out visit. (A high-quality color representation of this figure is available in the online issue.)
Figure 2 Time course values of adjusted eGFR and cGFR by ACCORD Renal Study Group. A: The changes in eGFR in units of mL/min/1.73 m2. B: Changes in cGFR in units of mL/min/1.73 m2. The horizontal trial time point axis is not shown to scale. The study group trends are shown as: black circles, fenofibrate cases; red triangles, fenofibrate controls; blue crosses, placebo controls. Base, baseline visit; M4, month 4 visit; Close, close-out visit; Post, postclose-out visit. (A high-quality color representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 149

Metadata

Authors
Mychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., Sperl-Hillen, J., Bonds, D. E., & Ginsberg, H. N.
Affiliations
  • University of Virginia (US)
  • Wake Forest University Health Sciences (US)
  • University of North Carolina at Chapel Hill (US)
  • Memphis VA Medical Center (US)
  • G.V. (Sonny) Montgomery VA Medical Center (US)
  • New York Hospital Queens (US)
  • University of Washington (US)
  • University of Iowa (US)
  • Health Partners Research Foundation, Minneapolis, Minnesota
  • National Institutes of Health (US)
  • Columbia University (US)
Corresponding author
Mychaleckyj, Josyf C.
Venue
Diabetes Care
Published
2012-04-11
Volume
35
Issue
5
Pages
1008-1014
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2022162088
Cited by
149
References
20
Citations by year
2026: 10 · 2025: 10 · 2024: 8 · 2023: 12 · 2022: 9 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 10 · 2017: 13 · 2016: 13 · 2015: 12 · 2014: 13 · 2013: 11 · 2012: 3
FWCI
9.85
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • Hispana (submittedVersion)
  • UNC Libraries
Funders
  • American Diabetes Association
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Osiris Therapeutics
  • MannKind Corporation
  • Halozyme
  • Omron Healthcare
  • Bayer HealthCare
  • Novo Nordisk
  • National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
  • Centers for Disease Control and Prevention
  • National Institute on Aging
  • National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
  • National Eye Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
fenofibrate, serum creatinine, cystatin C, estimated glomerular filtration rate, type 2 diabetes, drug discontinuation, renal function recovery, lipid-lowering therapy, placebo comparison, cardiovascular risk in diabetes
MeSH terms
Aged, Hypolipidemic Agents, Creatinine, Glomerular Filtration Rate, Humans, Middle Aged, Fenofibrate, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants. https://app.cochat.ai/papers/10.2337/dc11-1811
The paper
Mychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., Sperl-Hillen, J., Bonds, D. E., & Ginsberg, H. N. (2012). Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants. Diabetes Care. https://doi.org/10.2337/dc11-1811

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.